Responses
Epidemiology/Health Services Research
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
Compose a Response to This Article
Other responses
No responses have been published for this article.